archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • News Archive
    week s meeting the Pharmaceutical Benefits Advisory Committee PBAC rejected CSL s funding application for its cervical cancer vaccine GARDASIL CSL applied to the PBAC for National Immunisation Program funding for the vaccine for three groups of women based on the use approved by the Therapeutic Goods Administration TGA An ongoing cohort of 11 12 year old girls delivered through a schools based program at the end of primary school

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562741033/prdetail.htm (2014-01-05)
    Open archived version from archive


  • News Archive
    that Mr David Simpson has been appointed a Director of the Company effective from 1 September 2006 Mr Simpson is the non executive Chairman of Aristocrat Leisure Limited and a Director of Lighthouse Foundation For many years Mr Simpson was Finance Director of Tabcorp Holdings Limited and before that Executive General Manager Finance of Southcorp Holdings Ltd CSL s Chairman Mr Peter Wade said that he was delighted that Mr

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562740423/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    About CSL Our Businesses Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom News Archive Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive CSL Full year Result Announcement for 2006 CSL Full year Result Announcement for 2006 Melbourne Australia 23 08 2006 CSL Limited today announced its operating result for the full year ended 30 June 2006 Download the full release

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562741752/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    and offshore group of companies together as a single global entity The changes are designed to present a consistent and compelling view of CSL as an Australian company operating in new and established markets around the world We are using CSL as the common foundation which means our international ZLB Behring plasma therapeutics business will be renamed CSL Behring In Australia we ve replaced CSL Pharmaceuticals with CSL Biotherapies which will support the manufacture sale and distribution of influenza vaccine worldwide CSL Bioplasma our Australian plasma therapeutics business will retain its name reflecting its unique position as Australia s national fractionator CEO Dr Brian McNamee said today This year CSL will be providing flu vaccine from Australia to international markets launching its Australian invented cervical cancer vaccine and further investing in solutions for pandemic flu it s time to bring a new brand into the 21st century which reflects what we actually do Dr McNamee said CSL was formerly known as the Commonwealth Serum Laboratories a Federal Government statutory authority and was privatised in 1994 at an estimated value of 300 million It is now a global specialty biopharmaceutical company providing a range of products to treat and prevent serious medical conditions with a market capitalisation of approximately 9 billion This year almost 200 million will be invested in medical research and development Headquartered in Melbourne Australia the CSL Group includes CSL Bioplasma CSL Biotherapies and CSL Behring incorporating ZLB Plasma Services With major facilities in Australia Germany Switzerland and US CSL has approximately 7500 employees working in 26 countries The business units within CSL will be renamed as follows CSL Behring previously known as ZLB Behring headquartered in King of Prussia outside Philadelphia USA and a global leader in plasma therapeutics ZLB Plasma Services will retain its current name

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562740511/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Search News by Date Contact CSL Home Newsroom News Archive CSL Announces Signing of a Merger Implementation Deed to Acquire Zenyth Therapeutics Limited Zenyth CSL Announces Signing of a Merger Implementation Deed to Acquire Zenyth Therapeutics Limited Zenyth Melbourne Australia 17 07 2006 CSL Limited CSL and Melbourne based biotech company Zenyth Therapeutics Limited Zenyth today announced a proposal under which CSL would acquire 100 of the issued shares in

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562740571/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Intendis GmbH a subsidiary of Schering AG has granted CSL Limited an exclusive license to market and distribute three of their better known products in Australia The products include Advantan TM a topical corticosteroid for the treatment of eczema Finacea TM for the treatment of rosacea and acne and Scheriproct TM used in the treatment of haemorrhoids This new arrangement offers an excellent fit with CSL s existing in licensed

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562740630/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    in recognition of the contingent payment 1 arising from the acquisition of Aventis Behring Dr McNamee CSL s Managing Director said I m very pleased to report that the company is performing well The formation and highly successful integration and financial performance of ZLB Behring and the recent approval of Gardasil 2 by the US Food and Drug Administration and Australia s Therapeutic Goods Administration have given me continuing confidence in the performance of the company Accordingly we have decided to raise a provision for the contingent payment arising from the acquisition of Aventis Behring Dr McNamee said A pre tax charge of US 250m A 330m which is consistent with the company s announcement at the time of the acquisition will be booked to the profit and loss account for the financial year ending 2006 In accordance with Australian equivalents to international financial reporting standards this will be reflected as an exceptional item OUTLOOK FOR 2006 REAFFIRMED The company reaffirmed its financial guidance provided at the first half result announcement on 22 February 2006 For the 2005 06 fiscal year the company expects to report a net profit after tax figure prior to the contingent payment provision in the region of 335 to 350 million For further information contact Mark Dehring Tel 613 9389 2818 1 On 31 March 2004 CSL Limited acquired the global plasma therapeutics business of Aventis Behring The consideration included contingent payments A cash payment or issue of shares at CSL Limited s discretion in the amount of USD 125 million to be made if the ordinary shareprice of CSL Limited rises above A 28 per share trigger price for a specified period To satisfy this requirement the volume weighted average shareprice of an ordinary share of CSL limited must remain above the trigger price

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562740306/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    News Archive CSL Limited Announces FDA Approval of its Licensee Merck Co Inc s Cervical Cancer Vaccine GARDASIL CSL Limited Announces FDA Approval of its Licensee Merck Co Inc s Cervical Cancer Vaccine GARDASIL Melbourne Australia 09 06 2006 CSL Limited today announced that its licensee Merck Co Inc has received approval from the U S Food and Drug Administration FDA of its cervical cancer vaccine GARDASIL for vaccination of girls and women between the ages 9 and 26 CSL s Managing Director Dr Brian McNamee said It is anticipated that with FDA approval now achieved GARDASIL will save the lives of many women This landmark medical breakthrough for Australian science is the culmination of 15 years involvement by CSL in the development of the product beginning with a research collaboration with Professor Ian Frazer and the University of Queensland GARDASIL is a quadrivalent human papillomavirus recombinant vaccine designed to prevent the majority of HPV related clinical diseases caused by HPV 6 11 16 and 18 HPV types 16 and 18 account for approximately 70 percent of cervical cancer cases HPV 6 and 11 cause approximately 90 percent of genital wart cases In the United States approximately 10 000 women

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1196562740364/prdetail.htm (2014-01-05)
    Open archived version from archive